Rocket Pharmaceuticals, Inc.
RCKT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001281895
In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.
Q3 2022 vs. Q2 2022
How the institutions holding Rocket Pharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 147 | 164 | +17 |
| Shares | 64.8M | 69.1M | +4.28M (+6.6%) |
| Value | $891.6M | $1.10B | +$209.6M (+23.5%) |
New holders (31)
Institutions that held Rocket Pharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (14)
Institutions that held Rocket Pharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Amitell Capital Pte Ltd | 97,331 | $1.34M |
| Ameriprise Financial Inc | 82,720 | $1.14M |
| Cinctive Capital Management LP | 80,000 | $1.10M |
| Qube Research & Technologies Ltd | 54,935 | $756.0K |
| Gilder Gagnon Howe & Co LLC | 29,659 | $408.0K |
| Parkman Healthcare Partners LLC | 26,677 | $367.0K |
| Allianz Asset Management GmbH | 20,470 | $282.0K |
| Veritable, L.P. | 12,211 | $168.0K |
| Baird Financial Group, Inc. | 10,661 | $147.0K |
| Ovata Capital Management Ltd | 2,900 | $40.0K |
| Simplex Trading, LLC | 452 | $6.00K |
| Dark Forest Capital Management LP | 265 | $4.00K |
| Fifth Third Bancorp | 103 | $1.00K |
| Captrust Financial Advisors | 104 | $1.00K |